|
1. Aleynik SI, Lieber CS. Polyenylphos-phatidylcholine corrects the alcohol-induced hepatic oxidative stress by restoring s-adenosylmethionine. Alcohol Alcohol. 2003 May;38(3):208-12.
2. Navder KP, Baraona E, Lieber CS. Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J Nutr. 1997 Sep;127(9):1800-6.
3. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003 Nov;27(11):1765-72.
4. Atoba MA, Olubuyide IO. The effects of essential phospholipid choline in HBs-Ag negative acute hepatitis. West Afr J Med. 1989 Oct;8(4):284-7.
5. Jenkins PJ, Portmann BP, Eddleston AL, Williams R. Use of polyunsaturated phosphatidyl choline in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver. 1982 Jun;2(2):77-81.
6. Niederau C, Strohmeyer G, Heintges T, Peter K, Gopfert E. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group. Hepatogastroenterology. 1998 May;45(21):797-804.
7. Klimov AN, Konstantinov VO, Lipovetsky BM, et al. “Essential” phospholipids versus nicotinic acid in the treatment of patients with type IIb hyperlipoproteinemia and ischemic heart disease. Cardiovasc Drugs Ther. 1995 Dec;9(6):779-84.
8. Dobiasova M, Stribrna J, Matousovic K. Effect of polyenoic phospholipid therapy on lecithin cholesterol acyltransferase activity in the human serum. Physiol Bohemoslov. 1988;37(2):165-72.
9. Navder KP, Baraona E, Lieber CS. Polyenylphosphatidylcholine decreases alcoholic hyperlipemia without affecting the alcohol-induced rise of HDL-cholesterol. Life Sci. 1997;61(19):1907-14.
10. Kirsten R, Heintz B, Nelson K, et al. Polyenylphosphatidylcholine improves the lipoprotein profile in diabetic patients. Int J Clin Pharmacol Ther. 1994 Feb;32(2):53-6.
11. Gurevich VS, Bondarenko BB, Mikhailova IA, et al. Evidence of combined therapy of dyslipoproteinemia by HMG-CoA reductase inhibitors and “essential” phospholipids. Clin Ter. 1993 Apr;142(4):329-34.
12. Khashimov K, Okur F, Orekhov AN, Kurdanov K, Tertov V. [Effect of lipostabil on cholesterol levels in atherosclerotic plaques of the human aorta and the aggregative capacity of thrombocytes (in vitro study)]. Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR. 1988;11(1):95-8.
13. Hendler SS, Rorvik D, eds. PDR for Nutritional Supplements. 1st ed. Montvale, NJ: Medical Economics Company, Inc: 2001:351-6.
14. Cohen BM, Renshaw PF, Stoll AL, et al. Decreased brain choline uptake in older adults. An in vivo proton magnetic resonance spectroscopy study. JAMA. 1995 Sep 20;274(11):902-7.
15. de la ME. Efficacy of CDP-choline in the treatment of senile alterations in memory. Ann NY Acad Sci. 1991;640:233-6.
16. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp Clin Pharmacol. 1995 Oct;17 Suppl B1-54.
17. Leyck S, Dereu N, Etschenberg E, et al. Improvement of the gastric tolerance of non-steroidal anti-inflammatory drugs by polyene- phosphatidylcholine (Phospholipon 100). Eur J Pharmacol. 1985 Oct 29;117(1):35-42.
18. Demirbilek S, Gurses I, Sezgin N, Karaman A, Gurbuz N. Protective effect of polyunsaturated phosphatidylcholine pretreatment on stress ulcer formation in rats. J Pediatric Surg. 2004 Jan;39(1):57-62.
19. Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM. Phopholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol. 1999 Jul;94(7):1818-22.
20. Conlay LA, Sabounjian LA, Wurtman RJ. Exercise and neuromodulators: choline and acetylcholine in marathon runners. Int J Sports Med. 1992 Oct;13 Suppl 1S141-2.
21. Buchman AL, Awal M, Jenden D, Roch M, Kang SH. The effect of lecithin supplementation on plasma choline concentrations during a marathon. J Am Coll Nutr. 2000 Nov;19(6):768-70. |